KSA Cardiac Markers Market Outlook to 2028

KSA Cardiac Markers Market Overview

The KSA Cardiac Makers Market has shown growth in past years. The Saudi Arabia cardiology devices market was valued at 980 million in 2023. This growth is further fueled by increasing awareness of early diagnosis and preventive healthcare measures.

The key players in the KSA cardiac markers market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Bio-Rad Laboratories, and Thermo Fisher Scientific. These companies are leading the market through continuous innovation, extensive research and development, and strategic partnerships.

In 2023, Abbott Laboratories announced the launch of a new high-sensitivity troponin test, which has been approved by the Saudi Food and Drug Authority (SFDA). This test improves the accuracy of diagnosing heart attacks and is expected to set a new standard in cardiac care in the region.

KSA Cardiac Markers Current Market Analysis

The Saudi government's Vision 2030 initiative aims to expand healthcare infrastructure, resulting in the establishment of 50 new cardiac care centres across the Kingdom in 2024. This expansion is driving the demand for cardiac markers as these centers require state-of-the-art diagnostic tools.

Over the next five years, the integration of AI and machine learning technologies in cardiac marker diagnostics is expected to enhance the accuracy and efficiency of test results. AI algorithms will provide advanced data analysis, leading to more precise and timely diagnoses.

In 2023, the Western region, including major cities like Jeddah and Mecca, dominance is attributed to the concentration of top-tier healthcare facilities and a higher prevalence of cardiovascular diseases among its population.

KSA Cardiac Markers Market Segmentation

The KSA Cardiac Markers Market is segmented into distribution channels like product type, application, and region.

By Product Type: The Cardiac Markers market in KSA is segmented into different product types like troponin, creatine kinase-MB, and myoglobin. In 2023, Troponin dominates due to its high sensitivity and specificity in detecting myocardial infarctions, making it the gold standard in cardiac diagnostics.

By Application: The Cardiac Markers market in KSA is segmented application into Acute Coronary Syndrome (ACS), Myocardial Infarction, and Heart Failure. In 2023, Acute Coronary Syndrome (ACS) dominates due to lifestyle factors such as diet and physical inactivity, necessitating the use of cardiac markers for early and accurate diagnosis.

By Region: The Cardiac Markers market in KSA is segmented into different regions like North, South, East, and West. The western region dominates in 2023 due to the concentration of top-tier healthcare facilities and the higher prevalence of cardiovascular diseases among its population.

KSA Cardiac Markers Market Competitive Landscape

Company

Establishment Year

Headquarters

Abbott Laboratories

1888

Illinois, USA

Roche Diagnostics

1896

Basel, Switzerland

Siemens Healthineers

1847

Erlangen, Germany

Bio-Rad Laboratories

1952

California, USA

Thermo Fisher Scientific

1956

Massachusetts, USA

PT Trafo Kontrol: PT Trafo Kontrol, one of the leading Cardiac Markers manufacturers in KSA, announced a $50 million investment in 2023 to expand its production capacity by 30%. This expansion will enable the company to better meet the growing demand for cardiac markers in the country.

Siemens Healthineers: Siemens Healthineers announced a strategic partnership with a leading Saudi hospital in 2024 i.e. King Faisal Specialist Hospital and Research Centre (KFSH&RC) to introduce state-of-the-art cardiac diagnostic tools. This collaboration has substantially increased the hospital's diagnostic capacity, showcasing the impact of such partnerships on healthcare quality.

Thermo Fisher Scientific: Thermo Fisher Scientific launched a new point-of-care testing device for cardiac markers in 2024. This device provides results within 10 minutes, revolutionizing emergency cardiac care by enabling timely intervention and improving patient outcomes.

KSA Cardiac Markers Market Analysis

KSA Cardiac Markers Market Growth Drivers:

Increasing Prevalence of Cardiovascular Diseases: The rising incidence of cardiovascular diseases in Saudi Arabia has increased the demand for cardiac markers. In 2024, over 400,000 new cases of cardiovascular conditions were reported, underscoring the urgent need for advanced diagnostic tools to manage these conditions effectively.

Increased R&D Activities: In 2024, major players in the cardiac markers market invested over USD 200 million in research and development to innovate and improve diagnostic accuracy. These R&D efforts are expected to lead to the introduction of more sensitive and specific cardiac markers in the market.

High Incidence of Lifestyle-related Disorders: In 2024, lifestyle-related disorders such as diabetes and hypertension, which are risk factors for cardiovascular diseases, affecting over 3 million individuals in Saudi Arabia. The high prevalence of these disorders is driving the demand for cardiac markers for early diagnosis and management.

KSA Cardiac Markers Market Challenges:

High Cost of Advanced Diagnostic Tests: The cost of advanced cardiac marker tests remains high, with an average cost of USD 150 per test in 2024, making them less accessible to lower-income populations. This financial barrier limits widespread adoption and impacts overall market growth.

Supply Chain Disruptions: In 2024, several companies (Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Bio-Rad Laboratories) faced delays in obtaining approval for new cardiac marker tests, impacting their ability to launch innovative products on time.

Competition from Alternative Diagnostic Methods: Alternative diagnostic methods, such as imaging techniques, continue to pose competition to cardiac markers. In 2024, 1,500 healthcare facilities preferred imaging techniques over cardiac markers for certain diagnostic applications, impacting the market's growth potential.

KSA Cardiac Markers Market Government Initiatives:

Health Awareness Campaigns: In 2024, the Saudi Ministry of Health conducted nationwide health awareness campaigns, reaching over 5 million individuals. These campaigns emphasized the importance of early diagnosis and preventive healthcare, driving the demand for cardiac markers.

National Cardiovascular Disease Prevention Program: In 2024, the Saudi Ministry of Health launched a National Cardiovascular Disease Prevention Program with a budget of USD 100 million. The program focuses on early diagnosis and management of cardiovascular diseases, increasing the demand for cardiac markers across healthcare facilities.

Healthcare Professional Training Programs In 2024, the Saudi government launched training programs for healthcare professionals, focusing on the effective use of advanced diagnostic tools. Over 10,000 healthcare workers received training on the utilization of cardiac markers, improving diagnostic accuracy and patient care.

KSA Cardiac Markers Future Market Outlook

The KSA Cardiac Markers market is expected to grow in the coming years. The market is also likely to shift towards more organized with established players and online platforms expanding their reach.

KSA Cardiac Markers Future Market Trends

Expansion of Telemedicine Services: By 2028, telemedicine adoption is expected to increase substantially, particularly in remote and underserved areas, enhancing the reach of cardiac marker testing. This expansion will enable remote monitoring and consultation, improving access to quality healthcare for more than 2 million residents in rural areas.

Development of Multi-Analyte Tests: The development of multi-analyte tests, which can simultaneously detect multiple cardiac markers, will become more prevalent. These tests are expected to streamline the diagnostic process, with projected adoption in over 400 healthcare facilities by 2028.

Advancements in Point-of-Care Testing: By 2028, point-of-care devices are expected to account for over 500,000 cardiac marker tests conducted annually in emergency settings, reducing diagnosis time and enabling timely intervention, which is crucial for patient survival and recovery.
Please Note: It will take 5-7 business days to complete the report upon order confirmation